256results about How to "Early diagnosis" patented technology

The present invention relates to a method for analyzing a genotype using a target-specific nuclease and, specifically, to a method for diagnosing cancer or analyzing a genotype by removing wild type DNA or particular genotype DNA using a target-specific nuclease or a variant thereof to amplify or concentrate only a small amount of DNA which has a difference in variation, such as a mutation, or genotype, and to a method for separating target DNA sesusing a target-specific nuclease or a variant thereof. Such methods are novel paradigm methods contrary to existing simple target-specific nucleases for post-PCR recognition of normal genotype and carcinogenic genotype, and can be favorably used in the early diagnosis of cancer or analysis of similar genotypes.

The invention comprises methods for diagnosing the risk of onset of type 1 diabetes and for preventing the onset of type 1 diabetes. The genetic background, metabolomes, antibodies and diversity of gut microbiota of an individual can be used for diagnosis.

An apparatus, system and method provide data indicative of cardio-respiratory state of a patient. Two or more cardio-respiratory parameters of the patient are measured, and optionally monitored over time, the two or more cardio-respiratory parameters being different one from the other and being measured at a same anatomical part of said patient.

A system, an apparatus and a method for human health evaluation utilizing the TMT mapping technology is disclosed. The method comprises scanning body areas of a patient utilizing an infrared camera, detecting abnormalities in the body of the patient, analyzing abnormalities of the patient against information stored in a database, and reporting results to the patient in a pre-determined format. The method provides an earlier discovery of disease by mapping and analyzing abnormal temperatures changes in the body, which can help prevent the disease from progressing at an early stage.

The present invention relates to a method of determining the presence of a retinoblastoma protein (Rb)-mediated cancerous or pre-cancerous condition in a sample of fixed cells that involves exposing the sample to an antibody that recognizes phosphorylation of serine on the retinoblastoma protein (pS-Rb), and identifying cells in the sample that are recognized by the anti-O body to pS-Rb, where the recognition of pS-Rb in the sample determines the presence of an Rb-mediated cancerous or pre-cancerous condition. The method also involves identifying the presence of specific cell cycle markers and positive and negative cell cycle regulators to assess the stage of disease progression in a cancer patient having an (Rb)-mediated cancer. The present invention also relates to methods of assessing the efficacy of cancer therapy for an Rb-mediated cancer, determining the mechanism of cell cycle progression in an Rb-mediated cancer, and identifying cells predisposed to developing an Rb-mediated cancerous condition.

The invention discloses a prehospital first-aid system, an ambulance and a hospital end. The first-aid end comprises medical equipment, a camera and vehicle-mounted communication equipment. The vehicle-mounted communication equipment receives data sent by the medical equipment and the camera and transmits the received data to the hospital end. The hospital end comprises a within-hospital receive and dispatch end which comprises one or a plurality of networking data servers. Each data server is configurated to receive data from the first-aid end, to conduct agreement analysis, processing and storage on the received data, to send data to the first-aid end and to receive at least response information or data information or a control instruction. The prehospital first-aid system, the first-aid end and the hospital end achieve two-way communication between the prehospital and the first-aid end, not only achieve interaction of prehospital monitoring data, curing information and treatment spot audio and video information between a hospital and the first-aid end, but also enable the outside hospital first-aid process to be guided by hospital in time.

A system for detecting neural abnormalities associated with specific central nervous system disorders in patients suspected of suffering from said disorders and for assisting in assessing the staging of said disorders in patients suffering from said disorders. Magnetic resonance imaging (MRI) machines and functional magnetic resonance imaging (fMRI) techniques are used to generate fMRI time series image data with respect to a selected regions of interest in the brain known to be affected by given disorders in response to activation tasks known to induce neural activity specifically in these regions. The fMRI data is used in generating statistically based standards and profiles by which abnormalities can be identified and the staging of disorders can be assessed. The results are diagrammatically or graphically displayed so that the data, standards and profiles can be usefully compared.

The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

An X-ray image analyzing system, including:

an X-ray source for radiating an X-ray; an X-ray detector for detecting an X-ray image radiated onto an x-ray image detection surface, wherein phase contrast X-ray simple imaging is capable of being performed determining a trabecular bone index computing region, computing a trabecular bone index indicating a state of a trabecula from image data in the trabecular bone index computing region, determining a bone-flesh boundary index computing region by a second region determination method different from the first region determination method, and computing a bone-flesh boundary index indicating smoothness of a bone-flesh boundary from image data in the bone-flesh boundary index computing region.

A medical image display system is shown. The medical image display system includes, a fringe scanning type capturing apparatus or a Fourier transformation type capturing apparatus; an image processing section; a display section; and a control section. The capturing apparatus includes, an X-ray source; a first grating and a second grating; a subject table; and an X-ray detector. The image processing section generates a plurality of reconstructed images for diagnosis based on an image signal of a subject captured with the capturing apparatus. The display section displays at least two of the plurality of reconstructed images. The control section detects an abnormal candidate on each of the plurality of reconstructed images and controls display order of the plurality of reconstructed images displayed on the display section based on a result of detecting.

The invention relates to a convolutional neural network-based low-dosage CT image noise inhibition method. The convolutional neural network-based low-dosage CT image noise inhibition method comprisesthe following steps: (1) performing normalization processing on the input original low-dosage CT image L by utilizing the low-dosage CT image obtained through low tube current tube voltage scanning, evaluating the mean value and the standard deviation of the gray level of all the pixels of the low-dosage CT image, and subtracting the mean value from the L and dividing the standard deviation to obtain a CT image L0; (2) taking the acquired preprocessed low-dosage CT image L0 as input of the convolutional neural network and predicting a noise CT image D0 corresponding to a low-dosage CT image I;and (3) subtracting the predicted noise image D0 from the L0, multiplying the standard deviation of the low-dosage CT image and adding the mean value of the low-dosage CT image to acquire the denoised image H0. The low-dosage CT image is subjected to denoising processing by the convolutional neural network, so that the image is guaranteed to meet the diagnosis quality, the irradiation dosage of asubject is reduced, the detection rate of the focus is increased and the disease is diagnosed early.

A handheld optical coherence tomography imaging and tissue sampling system and method of imaging and sampling a tissue is disclosed. The method includes inserting a catheter probe into a biopsy needle. The biopsy needle can be attached to a hand-held scanning and sampling device. The biopsy needle is maneuvered to an investigation site. A three-dimensional image of the tissue at the investigation site is captured with the catheter probe.

The present invention aims to provide a time-of-flight based mass microscope system for an ultra-high speed multi-mode mass analysis, for using a laser beam or an ion beam simultaneously to enable both a low molecular weight analysis such as for drugs/metabolome/lipids/peptides and a high molecular weight analysis such as for genes/proteins, without being limited by the molecular weight of the object being analyzed, and for significantly increasing the measuring speed by using a microscope method instead of a microprobe method.

The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.

The present invention relates to a method and a kit for diagnosing and/or predicting the occurrence of cancer or the risk of contracting a cancer by measuring the concentration of a cancer screening antigen(CSA) in blood, which changes before the occurrence of the cancer in a patient. The method of diagnosing or predicting the occurrence of cancer or the risk of contracting a cancer comprising the steps of: determining a concentration of galectin-3 in a blood sample by reacting the blood sample with a monoclonal antibody of the galectin-3; comparing the determined concentration of the galectin-3 with concentration of the galectin-3 in a blood sample of a normal human; and predicting the risk of contracting a cancer if the determined concentration is greater than the concentration of the galectin-3 in blood of the normal human.

Methods and systems for determining whether brain tissue is indicative of a disorder, such as a neurodegenerative disorder, are provided. The methods and systems generally utilize data processing techniques to assess a level of congruence between measured parameters obtained from magnetic resonance imaging (MRI) data and simulated parameters obtained from computational modeling of brain tissues.

The invention provides a colloidal gold test strip for detecting an IgM antibody. The IgM antibody is a specific IgM antibody for nine respiratory tract infection pathogens, and the colloidal gold test strip comprises a sample pad, a conjugate pad, a nitrocellulose film and a water absorption pad which are attached to a polyvinyl chloride base plate in sequence; the conjugate pad is a glass fiber film wrapped with a rabbit-anti-human IgM antibody-colloidal gold conjugate; the nitrocellulose film is wrapped with 9 detection lines and 1 quality control line in sequence; the 9 detection lines are respectively a mycoplasma pneumoniae recombined antigen, a chlamydia pneumoniae recombined antigen, an influenza a virus antigen, an influenza B virus antigen, a sendai virus antigen, a legionella pneumophila antigen, a Coxiella burnetii antigen, a respiratory syncytial virus antigen and an adenovirus antigen, and the quality control line is a second antibody. The invention further provides a colloidal gold test strip card comprising the colloidal gold test strip and a colloid gold kit, a preparation method of the colloidal gold test strip card, and a method for realizing detection by adopting the colloidal gold test strip, the test strip card or the kit.

The present invention relates to the use of sleep spindles as a novel biomarker for early diagnosis of synucleinopathies, in particular Parkinson's disease (PD). The method is based on automatic detection of sleep spindles. The method may be combined with measurements of one or more further biomarkers derived from polysomnographic recordings.

The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. Portions of the method may be performed with the use of a microfluidic machine.